Skip to main content
Retour
Watch Compare

AXIM BIOTECHNOLOGIES, INC.

Qualité des données : 100%
AXIM
OTC Manufacturing Chemicals
0,01 €
0,00 € (0,00%)
Cap. Boursière: 1,93 M
Prix
0,01 €
Cap. Boursière
1,93 M
Fourchette du Jour
0,01 € — 0,01 €
Fourchette 52 Semaines
0,00 € — 0,03 €
Volume
223 916
Ouverture 0,01 €
Moyenne 50J / 200J
0,01 €
44,95% below
Moyenne 50J / 200J
0,01 €
36,84% below

Quick Summary

Points Clés

Revenue declined -52,85% annually over 5 years
Negative free cash flow of -752 995,0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 398,12%
Capital efficient — spends only 3,40% of revenue on capex

Croissance

Revenue Growth (5Y)
-52,85%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)345,27%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-4452,06%
Op. Margin-2490,35%

Sécurité

Debt / Equity
N/A
Current Ratio0,00
Interest Coverage-5,62

Valorisation

PE (TTM)
-0,47
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,5 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -4452,1 -41,5
Rev Growth 5Y % -52,9 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 345,27% Revenue Growth (3Y) -19,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -52,85% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 92 898,0 Net Income (TTM) -4,14 M
ROE N/A ROA -107,95%
Gross Margin N/A Operating Margin -2490,35%
Net Margin -4452,06% Free Cash Flow (TTM) -752 995,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,00
Interest Coverage -5,62 Asset Turnover 0,02
Working Capital -6,55 M Tangible Book Value -9,53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,47 Forward P/E N/A
P/B Ratio N/A P/S Ratio 20,79
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -38,99%
Market Cap 1,93 M Enterprise Value 7,90 M
Per Share
EPS (Diluted TTM) -0,02 Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) -200,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,40% FCF Conversion 18,21%
SBC-Adj. FCF -914 458 Growth Momentum 398,12

Income Statement

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020 FY2019
Revenue 39 518,0 8 875,0 60 460,0 0,0 799 483,0
Net Income -8,06 M -6,24 M -16,03 M -6,41 M -6,45 M
EPS (Diluted) -0,04 0,04 -0,12 -0,06 —
Gross Profit — — — 0,0 223 789,0
Operating Income -2,75 M -4,65 M -13,97 M -4,95 M -6,51 M
EBITDA — — — — —
R&D Expenses 125 496,0 153 697,0 284 869,0 426 708,0 2,45 M
SG&A Expenses 2,24 M 4,08 M — — —
D&A 427 019,0 426 126,0 2,12 M — —
Interest Expense 140 000,0 140 000,0 247 792,0 234 754,0 248 636,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020 FY2019
Total Assets 4,12 M 4,21 M 5,32 M 11,31 M 1,69 M
Total Liabilities 11,78 M 9,04 M 7,66 M 9,75 M 8,45 M
Shareholders' Equity -7,66 M -4,83 M -2,34 M 1,57 M -6,76 M
Total Debt — — 180,0 180,0 5 000,0
Cash & Equivalents — 47 282,0 452 963,0 457 181,0 511 630,0
Current Assets 156 457,0 103 979,0 636 613,0 713 104,0 1,64 M
Current Liabilities 5,98 M 3,39 M 2,58 M 1,50 M 3,40 M